Diagnosing the decline in pharmaceutical R&D efficiency
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For over fifty years, the pharmaceutical industry has seen the cost of developing drugs increase exponentially from tens of millions in the 1950s to billions of dollars today, even when the data is adjusted for inflation [1].”
From Drug design on quantum computers (2024) · doi:10.1038/s41567-024-02411-5 · cites this paper as [1]
Citations
Cites
Collective dynamics of ‘small-world’ networks
Watts, D. J., & Strogatz, S. H. (1998) · Nature · doi:10.1038/30918 · Cited by 43,060
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“It is hard to look at the genesis of drugs like crizotini”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“First, estimates of the number of potential drug target”
Background
Research works printed but not linked: 6
- Ruffolo, R. R. Engineering success: Wyeth redefines its research & development organisation. Drug Discovery World website [online] , (2005).
- Young, M. P. Prediction v Attrition. Drug Discovery World website [online] , (2008).
- Healy, D. The Psychopharmacologists: Volume 2 93–118 (Hodder Arnold, London, 1999).
- Healy, D. The Psychopharmacologists: Volume 2 259–264 (Hodder Arnold, London, 1999).
- Mathieu, M. P. (ed.) Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2010/2011 163–261 (Barnett International, Needham, Massachusetts, 2010).
- Munos, B. How to avert biopharma's R&D crisis. In Vivo 29, 2011800050 (2011).
Cited by
Items 601–700 of 1,002
Branchi, I. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104678 · Cited by 31
“…linked to mental illness through a molecular approach is still arduous and imprecise and translating the increasing scientific knowledge into novel and effective therapeutic strategies for brain disorders has advanced only limitedly (Hyman, 2012; Murray et al., 2021; Scannell et al., 2012).”
BackgroundLanguage Models in Molecular Discovery
Janakarajan, N., Erdmann, T., Swaminathan, S., Laino, T., & Born, J. (2024) · Springer eBooks · doi:10.1007/978-981-97-4828-0_7 · Cited by 32
“The intricacy of the problem is typically attested by an exorbitant attrition rate in in vitro screenings [77], the sheer size of the chemical space [68] and the frequency of serendipity [40].”
BackgroundDrugging the undruggable: gabapentin, pregabalin and the calcium channel α2δ subunit
Offord, J., & Isom, L. L. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2016.1173010 · Cited by 27
“Identifying new drugs has proven difficult in recent years (Scannell et al., 2012).”
BackgroundSilva, P. J., Schaibley, V. M., & Ramos, K. S. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1401-2 · Cited by 30
“[17] showed that R&D productivity (as measured by the number of approved drugs) has declined along a somewhat predictable trend deemed Eroom’s law (Moore’s Law, spelled backward).”
BackgroundElebring, T., Gill, A. L., & Plowright, A. T. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.04.009 · Cited by 31
Quantum-machine-assisted drug discovery
Zhou, Y., Chen, J., Cheng, J., Cao, X., Zhang, Y., Karemore, G., Žitnik, M., Chong, F. T., Liu, J., Fu, T., et al. (2026) · npj Drug Discovery. · doi:10.1038/s44386-025-00033-2 · Cited by 33
“Hours to days on distributed systems; Limited by classical [205–207] 100-200 qubits for small-scale optimization; Minutestohours runtime[49,197] 500-1000 logical qubits; Minutes runtime; Quantum [197] QAOA Currently limited to proof-of-concept; 100-500noisy qubits[36,197] 1000-5000 logical qubits;…”
Imaging therapeutic peptide transport across intestinal barriers
Larsen, J. B., Taebnia, N., Dolatshahi‐Pirouz, A., Eriksen, A. Z., Hjørringgaard, C. U., Kristensen, K., Larsen, N. W., Larsen, N. B., Marie, R., Mündler, A.-K., et al. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00024a · Cited by 27
Alharbi, E., Skeva, R., Juty, N., Jay, C., & Goble, C. (2021) · Data Intelligence · doi:10.1162/dint_a_00109 · Cited by 30
“Over the past two decades, the cost of drug R&D has risen ten-fold, whereas the number of approved new drugs has steadily declined [15, 16].”
BackgroundRobb, A., Rohrschneider, M., Booth, A., Carter, P., Walker, R. M., & Andrews, G. (2022) · Technovation · doi:10.1016/j.technovation.2022.102461 · Cited by 26
Kann, S. H., Shaughnessey, E. M., Coppeta, J. R., Azizgolshani, H., Isenberg, B. C., Vedula, E. M., Zhang, X., & Charest, J. L. (2022) · Microsystems & Nanoengineering · doi:10.1038/s41378-022-00442-7 · Cited by 26
In Silico Clinical Trials: Is It Possible?
Arsène, S., Parès, Y., Tixier, E., Granjeon-Noriot, S., Martin, B., Bruezière, L., Couty, C., Courcelles, E., Kahoul, R., Pitrat, J., et al. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3449-3_4 · Cited by 26
Synthetic Macrocycles in Small-Molecule Drug Discovery
Vendeville, S., & Cummings, M. D. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00023-5 · Cited by 32
Signaling networks in MS: A systems-based approach to developing new pharmacological therapies
Kotelnikova, E. A., Bernardo-Faura, M., Silberberg, G., Kiani, N. A., Messinis, D. E., Melas, I. N., Artigas, L., Schwartz, E., Mazo, I. A., Masso, M., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514543339 · Cited by 28
Investigating the effects of Orexin-A on thermogenesis in human deep neck brown adipose tissue
Pino, M. F., Divoux, A., Simmonds, A. V., Smith, S. R., & Sparks, L. M. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.155 · Cited by 26
International Strategy for Sustainable Growth in Multinational Pharmaceutical Companies
Teramae, F., Makino, T., Lim, Y., Sengoku, S., & Kodama, K. (2020) · Sustainability · doi:10.3390/su12030867 · Cited by 31
Cavalli, E., Battaglia, G., Basile, M. S., Bruno, V., Petralia, M. C., Lombardo, S. D., Pennisi, M., Kalfin, R. E., Tancheva, L. P., Fagone, P., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10030166 · Cited by 27
“The rest of the molecules are dropped because of toxicity issues or lack of efficacy [22,23].”
BackgroundMaldi Imaging Ms Analysis of Drug Distribution in Tissue: The Right Time!(?)
Castellino, S. (2012) · Bioanalysis · doi:10.4155/bio.12.251 · Cited by 26
Chemical Philanthropy: A Path Forward for Antibiotic Discovery?
Hansford, K. A., Blaskovich, M. A. T., & Cooper, M. A. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0029 · Cited by 26
Analysis of FDA-approved imaging agents
Kinch, M. S., & Woodard, P. K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.03.006 · Cited by 25
Filling the drug discovery gap: is high-content screening the missing link?
Dorval, T., Chanrion, B., Cattin, M., & Stephan, J. P. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.07.002 · Cited by 25
Excipient-Free Pure Drug Nanoparticles Fabricated by Microfluidic Hydrodynamic Focusing
Arzi, R. S., Kay, A., Raychman, Y., & Sosnik, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040529 · Cited by 25
MGATRx: Discovering Drug Repositioning Candidates Using Multi-View Graph Attention
Yella, J., & Jegga, A. G. (2021) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3082466 · Cited by 26
“As per an estimate, the total average cost for developing a new drug – from discovery to approval - ranges from $2 billion - $3 billion and takes about 13–15 years [1].”
BackgroundOrgan-on-a-Chip for Drug Screening: A Bright Future for Sustainability? A Critical Review
Feitor, J. F., Brazaca, L. C., Lima, A. M., Ferreira, V. G., Kassab, G., Bagnato, V. S., Carrilho, E., & Cardoso, D. R. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01454 · Cited by 27
Against the singularity hypothesis
Thorstad, D. (2024) · Philosophical Studies · doi:10.1007/s11098-024-02143-5 · Cited by 34
“10 By way of illustration, the number of FDA-approved drugs per billion dollars of inflation-adjusted research expenditure decreased from over forty drugs per billion in the 1950s to less than one drug per billion in the 2000s (Scannell et al., 2012).”
Open PHACTS: A Semantic Knowledge Infrastructure for Public and Commercial Drug Discovery Research
Harland, L. (2012) · Lecture notes in computer science · doi:10.1007/978-3-642-33876-2_1 · Cited by 25
“In an industry facing major economic pressures [3], the idea of combining forces to “get more for less” is very attractive and is arguably the only feasible route to dealing with the exponentially growing information landscape.”
BackgroundIdentification of in vitro and in vivo disconnects using transcriptomic data
Otava, M., Shkedy, Z., Talloen, W., Verheyen, G. R., & Kasim, A. (2015) · BMC Genomics · doi:10.1186/s12864-015-1726-7 · Cited by 29
“A relatively small number of drugs are being approved, while research costs are increasing, patents are expiring, and both governments and health insurance companies are pushing for cheaper medications [2].”
BackgroundImproving the predictive value of interventional animal models data
Zeiss, C. J. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.015 · Cited by 25
“Given similar conclusions for other diseases [1,2,21], and the dismal therapeutic reality of AD, this is not a surprise.”
BackgroundPatents as a Spur to Subsequent Innovation? Evidence from Pharmaceuticals
Gilchrist, D. S. (2016) · American Economic Journal Applied Economics · doi:10.1257/app.20150373 · Cited by 25
Old wines in new bottles: Repurposing opportunities for Parkinson's disease
Kakkar, A. K., Singh, H., & Medhi, B. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.04.023 · Cited by 26
Academic Discovery of Anticancer Drugs: Historic and Future Perspectives
Carugo, A., & Draetta, G. F. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055645 · Cited by 30
“F or p er so na l u se o nl y. clear, not only to identify potential drug targets but also to define molecular biomarkers to predict response ahead of investing in large, randomized clinical trials (Scannell et al. 2012).”
BackgroundNew designs in early clinical drug development
Mansinho, A., Boni, V., Miguel, M. J. D., & Calvo, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz191 · Cited by 28
Camp, K., Lloyd-Puryear, M. A., Yao, L. P., Groft, S. C., Parisi, M. A., Mulberg, A. E., Gopal-Srivastava, R., Cederbaum, S. D., Enns, G. M., Ershow, A. G., et al. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.05.008 · Cited by 26
“Total spending on all health-related research has tripled since the ODA and successive legislationwere enacted [24,25].”
Background3D Bioprinting Models for Glioblastoma: From Scaffold Design to Therapeutic Application
Branco, F., Cunha, J., Mendes, M., Sousa, J., & Vitorino, C. (2025) · Advanced Materials · doi:10.1002/adma.202501994 · Cited by 28
Blau, C. A., Ramirez, A. B., Blau, S. H., Pritchard, C. C., Dorschner, M. O., Schmechel, S. C., Martins, T. J., Mahen, E. M., Burton, K. A., Komashko, V., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0003 · Cited by 24
“J Natl Compr Canc Netw 2016;14(1):8–17”
BackgroundReprogramming of antibiotics to combat antimicrobial resistance
Dubey, K. K., Indu, & Sharma, M. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000168 · Cited by 26
Visanji, N. P., Madan, P., Lacoste, A. M. B., Buleje, I., Han, Y., Spangler, S., Kalia, L. V., Alford, S. H., & Marras, C. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5176 · Cited by 24
Network module‐based drug repositioning for pulmonary arterial hypertension
Wang, R., & Loscalzo, J. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12670 · Cited by 28
“Organ-on-a-chip”-based physiologically relevant pharmacokinetic models
Tambe, V., Desai, N., Rajpoot, K., & Tekade, R. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814425-1.00024-3 · Cited by 24
Monobodies as tool biologics for accelerating target validation and druggable site discovery
Akkapeddi, P., Teng, K. W., & Koide, S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00188d · Cited by 24
Inhibition of PDK3 by artemisinin, a repurposed antimalarial drug in cancer therapy
Anwar, S., DasGupta, D., Azum, N., Alfaifi, S., Asiri, A. M., Alhumaydhi, F. A., Alsagaby, S. A., Sharaf, S. E., Shahwan, M. J., & Hassan, M. I. (2022) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2022.118928 · Cited by 25
Image-based generation for molecule design with SketchMol
Wang, Z., Chen, Y., Ma, P., Yu, Z., Wang, J., Liu, Y., Ye, X., Sakurai, T., & Zeng, X. (2025) · Nature Machine Intelligence · doi:10.1038/s42256-025-00982-3 · Cited by 37
“The pharmaceutical industry has long faced the Eroom’s law 1 , according to which despite escalating investments, the number of new drugs developed per billion dollars has halved every nine years since 1950.”
Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD
Bihlet, A. R., Karsdal, M. A., Bay‐Jensen, A., Read, S., Kristensen, J. H., Sand, J. M. B., Leeming, D. J., Andersen, J. R., Lange, P., & Vestbo, J. (2015) · CHEST Journal · doi:10.1378/chest.15-0296 · Cited by 24
Rchemcpp: a web service for structural analoging in ChEMBL, Drugbank and the Connectivity Map
Klambauer, G., Wischenbart, M., Mahr, M., Unterthiner, T., Mayr, A., & Hochreiter, S. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv373 · Cited by 24
“One strategy to remedy the steadily declining efficiency of the drug development process is to utilize the vast information on chemical compounds that is already present in public and internal databases (Arrowsmith, 2011; Scannell et al. , 2012).”
BackgroundThe Cost-Effectiveness of Periodic Safety Update Reports for Biologicals in Europe
Bouvy, J. C., Ebbers, H. C., Schellekens, H., & Koopmanschap, M. A. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.13 · Cited by 24
Mas, C., Boda, B., Caul-Futy, M., Huang, S., Wiszniewski, L., & Constant, S. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.01.012 · Cited by 27
Active Search for Computer‐aided Drug Design
Oglić, D., Oatley, S. A., Macdonald, S. J. F., Mcinally, T., Garnett, R., Hirst, J. D., & Gärtner, T. (2018) · Molecular Informatics · doi:10.1002/minf.201700130 · Cited by 24
Moridi, M., Ghadirinia, M., Sharifi‐Zarchi, A., & Zare‐Mirakabad, F. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3165-y · Cited by 24
“More than 90% of drugs fail during the development stages due to inefficacy or high toxicity [1, 2].”
BackgroundBizzarri, M., Giuliani, A., Monti, N., Verna, R., Pensotti, A., & Cucina, A. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.02.010 · Cited by 26
Truong, J. Q., George, A., & Holien, J. K. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00213a · Cited by 27
Collins, J. M., Reizes, O., & Dempsey, M. K. (2016) · IEEE Journal of Translational Engineering in Health and Medicine · doi:10.1109/jtehm.2016.2609915 · Cited by 24
“While the low-range may be $100K for an App and a few $Million for a consumer device, it now costs about $2 Billion to bring a new drug to the market [4].”
BackgroundRole of Academic Drug Discovery in the Quest for New CNS Therapeutics
Yokley, B. H., Hartman, M. E., & Slusher, B. S. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00040 · Cited by 24
Artificial intelligence in drug discovery — what it is, where we stand and the path forward
Bender, A., Thomas, M. C., Scannell, J. W., Shaywitz, D. A., Ghiandoni, G. M., Greener, J. G., Pruteanu, L.-L., Jacobson, R. D., Handa, K., Hirano, M., et al. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01496-2 · Cited by 41
“In biopharma R&D, a critical contextual factor is the increasing cost required to achieve an approved drug (‘Eroom’s Law’ 132 ), exerting a pressure on pharmaceutical companies to change processes.”
Self-citationDenny, J. C. (2014) · Yearbook of Medical Informatics · doi:10.15265/iy-2014-0015 · Cited by 25
“The cost of generating new therapeutics has risen dramatically over the past 60 years, with each new drug costing about 80-fold more in 2010 than 1960 in inflation-adjusted terms [58].”
BackgroundWang, Y.-C., Wu, Y., Choi, J. Y., Allington, G., Zhao, S., Khanfar, M., Yang, K., Fu, P.-Y., Wrubel, M., Yu, X., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020175 · Cited by 25
SCHUBERT, W. J. (2013) · Journal of Molecular Recognition · doi:10.1002/jmr.2326 · Cited by 23
“Together with an increasing body of similar critical analyses, the recent detailed study and conclusions of Scannell et al. (2012) have evoked considerable scientific attention: “R&D (in the pharmaceutical industry) was more efficient several decades ago when many research activities that are today…”
BackgroundIn silicotools used for compound selection during target-based drug discovery and development
Caldwell, G. W. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1043885 · Cited by 25
“…unacceptable safety issues (Phase I) possibly due to off-target effects or failure of animal models to translate to humans and lack of efficacy (Phase II) possibly due to limiting target engagement issues or selecting targets that do not significantly influence the disease pathogenesis [5,8-16] .”
BackgroundInfluentialResearch and development productivity map: visualization of industry status
Shimura, H., Masuda, S., & Kimura, H. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12126 · Cited by 23
“However, the ratio of NMEs to R&D expenditure has declined by roughly 50% every 9 years since 1950.(2,3) Some studies suggest that development risk has remained relatively stable between the 1970s and 1990s, but that clinical trials have since become more complex, and as a result, more expensive.”
BackgroundWard, D. J., Martino, O. I., Simpson, S., & Stevens, A. J. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002088 · Cited by 23
The analysis of the market success of FDA approvals by probing top 100 bestselling drugs
Polański, J., Bogocz, J., & Tkocz, A. (2016) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-016-9912-5 · Cited by 23
“that have been approved per billion US dollars spent on R&D, which has halved roughly every nine years since 1950 [1].”
BackgroundNayroles, G., Frybourg, S., Gabriel, S., Kornfeld, A., Antoñanzas, F., Espín, J., Jommi, C., Martini, N., de Pouvourville, G., Tolley, K. H., et al. (2017) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2017.1298190 · Cited by 23
“Although investment in pharmaceutical research and development (R&D) has shown continual increase, productivity has been declining over the last decade.[1] Therapeutic innovation has become more challenging and pharmaceutical companies are looking for solutions to reduce the high attrition rate and offer patients bett…”
BackgroundAn overview of FDA-approved vaccines & their innovators
Griesenauer, R. H., & Kinch, M. S. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1383159 · Cited by 23
Innovation in Oncology Drug Development
Huber, M., & Huber, B. E. (2019) · Journal of Oncology · doi:10.1155/2019/9683016 · Cited by 24
“Estimating the perceived decline in productivity, it appears that for every 1 billion US dollars spent, there is a decrease by half the number of new drugs approved over each advancing decade [6].”
BackgroundTowards FAIR protocols and workflows: the OpenPREDICT use case
Çelebi, R., Moreira, J., Hassan, A., Ayyar, S., Ridder, L., Kuhn, T., & Dumontier, M. (2020) · PeerJ Computer Science · doi:10.7717/peerj-cs.281 · Cited by 26
“the need for new approaches in drug discovery (Scannell et al., 2012).”
BackgroundAssembling the Puzzle of Taxifolin Polymorphism
Terekhov, R. P., Selivanova, I. A., Tyukavkina, N. A., Ilyasov, I. R., Жевлакова, А. К., Dzuban, A. V., Bogdanov, A. G., Davidovich, G. N., Shilov, G. V., Utenishev, A. N., et al. (2020) · Molecules · doi:10.3390/molecules25225437 · Cited by 23
“That is why pharmaceutical companies are poised to invest more money in research [1,2].”
BackgroundSuay‐García, B., Falcó, A., Bueso-Bordils, J. I., Antón-Fos, G. M., Pérez‐Gracia, M. T., & Aleman, P. (2020) · Pharmaceuticals · doi:10.3390/ph13120431 · Cited by 23
“Along these lines, drug repurposing offers an alternative method for the fast and cost-effective identification of new therapeutic agents [20,21].”
Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics
Lam, M., Chen, C., Ge, T., Xia, Y., Hill, D. W., Trampush, J. W., Yu, J., Knowles, E., Davies, G., Stahl, E. A., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01023-4 · Cited by 26
“Such drug repurposing efforts also serve to reduce the high rate of failure associated with novel drug discovery [27].”
The value of translational biomarkers to phenotypic assays
Swinney, D. C. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00171 · Cited by 23
“It is well documented that this approach has not produced the desired results and in fact productivity has dramatically decreased (Scannell et al., 2013).”
BackgroundInfluentialStrategies for Skeletal Muscle Targeting in Drug Discovery
Ebner, D. C., Bialek, P., El‐Kattan, A. F., Ambler, C. M., & Tu, M. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140929095755 · Cited by 23
Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia
Lago, S. G., & Bahn, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00205 · Cited by 23
The Importance of Triaging in Determining the Quality of Output from High-Throughput Screening
Jones, P. S., McElroy, S. P., Morrison, A. J., & Pannifer, A. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.121 · Cited by 23
Hospitals and innovation: Introduction to the special section
Gulbrandsen, M., Hopkins, M. M., Thune, T. M., & Valentin, F. (2016) · Research Policy · doi:10.1016/j.respol.2016.05.010 · Cited by 29
Zhao, M., Yuan, M., Yang, Y., & Xu, S. X. (2023) · IEEE/ACM Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2022.3225296 · Cited by 22
“However, in vitro techniques measuring binding affinity in laboratories are usually expensive and time-consuming 32 .”
BackgroundTracking 20 Years of Compound-to-Target Output from Literature and Patents
Southan, C., Varkonyi, P., Boppana, K., Jagarlapudi, S. A. R. P., & Mureşan, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077142 · Cited by 25
“The declining productivity of global pharmaceutical development, measured in terms of small-molecule New Chemical Entities (NCEs) factored against their rising cost, has been extensively analysed and commented on in recent years [1,2,3,4,5].”
BackgroundO’Duibhir, E., Carragher, N. O., & Pollard, S. M. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.11.001 · Cited by 22
“However, the anticipated increase in clinical approval rates of novel first-in-class therapies has not followed, indeed, the exponential increase in investment in reductionist TDD strategies has coincided with an overall decline in R&D productivity (Paul et al., 2010; Scannell et al., 2012).”
Alhourani, A. H., Tidwell, T., Bokil, A. A., Røsland, G. V., Tronstad, K. J., Søreide, K., & Hagland, H. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-89861-6 · Cited by 24
Mavroudis, P. D., Teutonico, D., Abós, A., & Pillai, N. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1180948 · Cited by 27
Physicochemical and DMPK In Silico Models: Facilitating Their Use by Medicinal Chemists
Ortwine, D. F., & Aliagas, I. (2013) · Molecular Pharmaceutics · doi:10.1021/mp3006193 · Cited by 22
Ideation and implementation of an open science drug discovery business model – M4K Pharma
Morgan, M. R., Roberts, O. G., & Edwards, A. M. (2018) · Wellcome Open Research · doi:10.12688/wellcomeopenres.14947.1 · Cited by 25
Drug Repurposing and Orphan Disease Therapeutics
Dhir, N., Jain, A., Mahendru, D., Prakash, A., & Medhi, B. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91941 · Cited by 22
DeCorte, B. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00176 · Cited by 22
Yamada, O., Chiu, S.-W., Takata, M., Abe, M., Shoji, M., Kyotani, E., Endo, C., Shimada, M., Tamura, Y., & Yamaguchi, T. (2020) · Clinical Trials · doi:10.1177/1740774520971254 · Cited by 26
“This traditional monitoring is cost-consuming, typically accounting for 25% of an average total clinical trial budget, or more with larger more complex clinical trials.(1,2) SDV results in correction of a small percentage of electronic case report form (CRF) data despite this considerable monetary investment, with mos…”
BackgroundMahlich, J., Bartol, A., & Dheban, S. (2021) · Health Economics Review · doi:10.1186/s13561-021-00302-6 · Cited by 22
Lead optimization attrition analysis (LOAA): a novel and general methodology for medicinal chemistry
Munson, M., Lieberman, H., Tserlin, E., Rocnik, J. L., Ge, J., Fitzgerald, M., Patel, V. F., & García-Echeverría, C. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.03.010 · Cited by 23
Immuno-detection by sequencing enables large-scale high-dimensional phenotyping in cells
van Buggenum, J. A. G. L., Gerlach, J. P., Tanis, S. E. J., Hogeweg, M., Jansen, P. W. T. C., Middelwijk, J., van der Steen, R., Vermeulen, M., Stunnenberg, H. G., Albers, C. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04761-0 · Cited by 24
The drug treatment deadlock in psychiatry and the route forward
Howes, O. D., & Baxter, L. (2023) · World Psychiatry · doi:10.1002/wps.21059 · Cited by 22
Microphysiological systems to advance human pathophysiology and translational medicine
Harriot, A. D., Ward, C. W., & Kim, D. (2024) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00087.2024 · Cited by 23
Li, M., Song, K., He, J., Zhao, M., You, G., Zhong, J., Zhao, M., Li, A., Chen, Y., Li, G., et al. (2025) · Nature Machine Intelligence · doi:10.1038/s42256-025-01095-7 · Cited by 30
Financial Returns on R&D: Looking Back at History, Looking Forward to Adaptive Licensing
Scannell, J. W., Hinds, S., & EVANS, R. M. (2015) · Reviews on Recent Clinical Trials · doi:10.2174/1574887110666150430151751 · Cited by 21
“Some orphan drugs are approved on the basis of trials in a few tens of patients, while some Phase III cardiovascular trials have recruited around 30,000 patients [12], etc.”
BackgroundSelf-citationOne Lab, Two Firms, Many Possibilities: On R&D Outsourcing in the Biopharmaceutical Industry
de Villemeur, É. B., & Versaevel, B. P. A. (2017) · Journal of Health Economics · doi:10.1016/j.jhealeco.2019.01.002 · Cited by 21
“While the number of new molecular entities and biologics that are approved annually by the US Food and Drug Administration (FDA) has remained around the same level since 1950, when measured per billion US dollars spent on R&D this number has halved roughly every 9 years (Scannell et al., 2012).”
Zhu, T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.562660 · Cited by 24
“As a result, the probability for small molecules to successfully reach the market has remained rather flat for 60 years, and the overall R&D efficiency has declined due to rising costs (7).”
BackgroundInfluentialOguntuyo, K., Schuftan, D. R., Guo, J., Simmons, D. W., Bhagavan, D., Moreno, J. D., Kang, P. W., Miller, E. W., Silva, J. R., & Huebsch, N. (2022) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2022.0053 · Cited by 23
Shi, H., Rath, E. M., Lin, R. C. Y., Sarun, K. H., Clarke, C. J., McCaughan, B. C., Ke, H., Linton, A., Lee, K. M. L., Klebe, S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973576 · Cited by 24
Biosynthesis of protein-based drugs using eukaryotic microalgae
Xie, Z., He, J., Peng, S., Zhang, X., & Kong, W. (2023) · Algal Research · doi:10.1016/j.algal.2023.103219 · Cited by 21
The Role of Artificial Intelligence in Revolutionizing Pharmacological Research
Bhatia, N., Khan, M. M. U., & Arora, S. (2024) · Current Pharmacology Reports · doi:10.1007/s40495-024-00367-x · Cited by 31
“Pharmacological research has historically grappled with substantial challenges—enormous costs, extended timelines, and frequent setbacks in drug development [1, 2].”
Lundkvist, J., Halldin, M. M., Sandin, J., Nordvall, G., Forsell, P. K. A. L., Svensson, S., Jansson, L., Johansson, G., Winblad, B. G., & Ekstrand, J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00102 · Cited by 22
“…increasing cost-constraints in the healthcare system mandating generics and parallel import, and not the least, more demanding regulatory requirements (Kola and Landis, 2004; Cuatrecasas, 2006; Schachter and Ramoni, 2007; Munos, 2009; Paul et al., 2010; Scannell et al., 2012; Slusher et al., 2013).”
BackgroundRodriguez, K. X., Howe, E. N., Bacher, E. P., Burnette, M. D., Meloche, J. L., Meisel, J. E., Schnepp, P. M., Tan, X., Chang, M., Zartman, J. J., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900266 · Cited by 21
Rusz, M., Rampler, E., Keppler, B. K., Jakupec, M. A., & Koellensperger, G. (2019) · Metabolites · doi:10.3390/metabo9120304 · Cited by 21
Teramae, F., Makino, T., Lim, Y., Sengoku, S., & Kodama, K. (2020) · Sustainability · doi:10.3390/su12135358 · Cited by 22
Are There Hidden Genes in DNA/RNA Vaccines?
Beaudoin, C. A., Bartas, M., Volná, A., Pečínka, P., & Blundell, T. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.801915 · Cited by 22
“Although small molecule inhibitors and inactivated or live attenuated virus vaccine candidates have been used to successfully treat infection by pathogenic viruses, the pipelines to bring these products into clinical use can require significant time and resources with potentially low success rates (5, 6).”
BackgroundFunctionality‐Independent DNA Encoding of Complex Natural Products
Ma, P., Xu, H., Li, J., Lu, F., Ma, F., Wang, S., Xiong, H., Wang, W., Buratto, D., Zonta, F., et al. (2019) · Angewandte Chemie · doi:10.1002/ange.201901485 · Cited by 22
Metadata
- Authors
- Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B.
- Corresponding author
- Scannell, Jack W.
- ORCID
- Scannell, Jack W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 191-200
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2028279608
- Cited by
- 1,981
- References
- 85
- Citations by year
- 2026: 135 · 2025: 123 · 2024: 144 · 2023: 126 · 2022: 141 · 2021: 173 · 2020: 178 · 2019: 144 · 2018: 138 · 2017: 133 · 2016: 155 · 2015: 136 · 2014: 108 · 2013: 103 · 2012: 41
- FWCI
- 47.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- new drug approvals, drug approval rates, drug development costs, regulatory policy, drug regulation, basic research
- MeSH terms
- Animals, Drug Industry, Pharmaceutical Preparations, Humans, Research, Drug Delivery Systems, Efficiency, Organizational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.